Ramosetron - Samyang Biopharmaceuticals Corporation
Alternative Names: Emestop FD Tab; Emestop oral disintegrating tablet; Ramosetron hydrochloride - Samyang Biopharmaceuticals CorporationLatest Information Update: 02 Oct 2021
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antiemetics; Benzimidazoles; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Nausea and vomiting
Most Recent Events
- 04 Aug 2021 Chemical structure information added
- 09 Jul 2021 Launched for Nausea and vomiting (Prevention, Chemotherapy-induced) in South Korea (PO) before July 2021 (Samyang Biopharmaceuticals Corporation website, July 2021)
- 01 Jul 2021 Registered for Nausea and vomiting (Chemotherapy-induced, Prevention) in South Korea (PO) before July 2021 (Samyang Biopharmaceuticals Corporation pipeline, July 2021)